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Managing disease- and procedure-related pain in 
children is paramount. Chronically ill children, 
especially those requiring repeated procedures or 
admissions, experience a significant burden of pain. 
If poorly managed, it has a negative impact on quality 
of life and parent-child relationships.[1] 
This article discusses aspects of pain management relevant to most 
stages of illness, but focuses on the terminal stage. According to the 
World Health Organization (WHO), the principles of palliative care 
are applicable to all children with chronic illnesses from the time 
of diagnosis.[2] Several studies demonstrate the importance of good 
pain management – not only for the child, but also for the parents 
and siblings.[3] Failure to manage terminal pain adequately may have 
a lasting impact on the family and result in complicated grief.[4] One 
of the most commonly expressed wishes of families of dying children 
is that the death is as pain-free as possible. This can be challenging 
for professionals and family alike. Some patients and families may 
request a home death, adding challenges that require creative 
solutions to try to meet this goal.
In these situations, the general practitioner, who is often more 
accessible to the family, may be called upon to provide support. This 
may be daunting for the generalist, especially if the child has been 
cared for mainly by paediatricians. 
Nonetheless, with good forward planning, excellent communication 
between generalist and specialist, and access to hospice- or home-
based care services in the community, this can be achieved, as 
demonstrated by the case study below.
From the outset, however, families must realise that sometimes 
matters just don’t develop according to plan. Short-term 
hospitalisation may be required to manage some complications, 
families may not be able to cope, or the impact on younger siblings 
may be too overwhelming. Admissions to a hospital or hospice may 
be necessary and should not be regarded as a failure.
Case study
John Daniels is the 11-year-old son of Mr and Mrs Daniels, a farming 
family from a rural area in South Africa. John was first diagnosed 
with acute lymphoblastic leukaemia at the age of 3 years. He went 
into remission after his first course of chemotherapy at a tertiary 
paediatric oncology centre in the nearest city, 1 000 km from the 
farm. During this time his mother moved in with family in the city 
to be with him, as he received treatment over 3 years. After being in 
remission for 2 years, John experienced his first relapse, and once 
again Mrs Daniels accompanied him to the city. The second treatment 
course was complicated by several episodes of profound neutropenic 
sepsis, during which John nearly lost his life. After being disease-free 
for 3 years, John has unfortunately relapsed again. Given the dismal 
prognosis following a second relapse, the systemic treatment-related 
implications and John’s last chemotherapy experience, a difficult 
decision was made, i.e. not to undertake any further active treatment. 
John’s wish is to die at home on the farm surrounded by family and 
friends. Like his mother, he is a deeply religious Christian and a 
very sensitive boy, wise beyond his years. He feels very guilty that he 
demanded so much of his mother’s time as a child to the detriment, 
he believes, of his sisters aged 15 and 9 years. Although he has a good 
relationship with his father, he feels that his father resents him for 
all the time his mother had to spend with him away from the farm. 
The current relapse was noticed during routine screening and John 
is currently clinically asymptomatic. The paediatric oncologist has 
written a letter to the local GP and hospice sisters in the rural area, 
requesting assistance from them in managing his end-of-life stage so 
that he can spend his last days on the farm.
What kind of pain would John 
experience as his disease progresses 
and how would this be assessed?
In managing the terminal phase of any chronic illness, it is useful 
to understand the natural pattern of progression of the specific 
underlying condition and plan for possible scenarios based on an 
understanding of the pathophysiology. Advance care planning may be 
a useful tool to help parents prepare themselves for any eventuality. [5] 
General practitioners can acquire the necessary knowledge, drugs 
and resources to successfully manage most complications and avoid 
unnecessary stress for themselves and the family. 
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In John’s case, the pathophysiological mechanisms resulting in 
painful symptoms are given in Table 1.
The cornerstone of good pain management is proper assessment. The 
gold standard of pain assessment is patient self-reporting, using the 
PQRST acronym: P = provoking and palliating factors, Q = quality 
and quantity, R = region and radiation, S = severity, and T = timing 
(Table 2).[7]
A particularly useful tool in evaluating multiple sites and sources of 
pain in leukaemia is the Eland body tool.[8] The child is given an outline 
drawing of the front and back of a child and is asked to select four 
coloured crayons or pencils: one for no pain, and one for mild, one for 
moderate and one for severe pain. The child may also choose to leave 
the unaffected parts of the body white. The child is then asked to colour 
his/her body as per the severity of the pain in the different parts of his/
her body according to his/her chosen colour code.
When assessing pain one must realise that pain is not only 
physical. Cicely Saunders, the founder of the modern hospice 
movement, was the first to describe the concept of ‘total pain’.[9] 
Apart from its physical manifestations, pain also has psychological, 
spiritual and social components, which are particularly important 
at the end of life. 
Psychologically, pain and its implications may evoke considerable 
anxiety. Failure to assess and manage this may make physical pain 
difficult to control. In John’s case, coming from a deeply religious 
family, it would be important to explore the possibility of existential 
or spiritual pain, as his faith may help him to be at peace with dying. 
Socially, John has feelings of guilt for having consumed so much of 
his mother’s time over the years to the perceived disadvantage of 
his sisters and father. Time at home would provide an important 
opportunity for him to address these perceptions and to experience a 
greater sense of intimacy with his whole family. 
How would the GP manage John’s 
escalating pain? 
Mrs Daniels, as John’s primary caregiver, is an important partner 
in managing John’s pain as his disease progresses. One of the key 
components of successful pain management at home is accurate 
reporting to detect changes in the patient’s condition and to carry out 
mutually agreed instructions. The assistance of a home-based care 
worker or hospice nurse to provide an objective second opinion is 
particularly useful, as objectivity may be lost if the primary caregiver 
becomes overwhelmed. 
In managing John’s pain, the following broad management 
principles apply:
Non-drug measures useful in managing pain in children are given 
in Table 3.[10] 
General principles of pain management
• Determine and treat the underlying cause (where possible) of 
pain, including non-physical causes
• Relieve pain without creating new symptoms or unwanted 
side-effects
• Consider both drug and non-drug interventions
• Consider whether treatment is beneficial to the individual 
patient
Table 2. PQRST acronym for pain assessment[7]
P Palliating and provoking factors What makes the pain better? What makes it worse?
Q Quality and quantity Descriptions of the nature of the pain help to determine whether it is nociceptive (sharp, well 
localised) or neuropathic (shooting pain)
R Region and radiation Helps with localisation, determining source of pain
S Severity Scales may be useful to rate severity and monitor response to treatment, e.g. face, legs, activity, cry, 
consolability (FLACC), faces scale (revised) or visual analogue scale (VAS)
T Timing Time of day, how long it lasts
Table 3. Non-drug measures for pain control
Counter-irritation Psychological methods
Heat Distraction
Cold Imagery
Touch/massage Relaxation
Transcutaneous electrical nerve 
stimulation (TENS)
Cognitive-behavioural therapy
Acupuncture Music therapy
Vibration Biofeedback
Aromatherapy Hypnosis
Table 1. Pathophysiology of pain in leukaemia
Site/system Pathology Symptom
Central nervous 
system
Meningeal 
infiltration
Headache
Neck stiffness
Peripheral nervous 
system
Chemotherapy-
related nerve 
damage
Peripheral 
neuropathy
Lymphatic system Lymphatic 
infiltration
Splenic infiltration
Nociceptive and/or 
neuropathic pain
Abdomen Hepatic infiltration
Capsular stretch
Abdominal node 
infiltration
Ileus
Nociceptive and/or 
neuropathic pain
Bone Cortical infiltration
Pathological 
fractures
Periosteal stretch
Infiltration of 
haversian canals
Nociceptive bone 
pain
Neuropathic bone 
pain
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As John’s pain will probably be mostly of bone origin, but could 
also include abdominal pain and headache, the pathophysiological 
mechanisms include both nociceptive and neuropathic mechanisms 
necessitating the use of classic analgesics and co-analgesics (previously 
called adjuvants).
The gold standard of cancer pain management is provided by the 
WHO 3-step ladder as shown in Fig. 1.[11] 
Doses for and notes on commonly used analgesics in children are 
given in Table 4.
John’s pain may initially be manageable with weak opioids 
such as tilidine (Valoron) in combination with paracetamol. The 
cumbersome drop formulation and expense of tilidine may limit 
its use; if syrups are preferred, the drops can be added to liquid 
paracetamol. In the public sector, morphine is more commonly 
given to outpatients. According to the new WHO guidelines, 
a lower dose of morphine may be used at step 2 of the WHO 
ladder.[12] Because of its variable bioavailability, codeine is no 
longer recommended for pain management in children.[13] An 
alternative weak opioid that may be used is tramadol, although 
its use is off licence in patients <18 years. To optimise dose 
increases, single agents rather than combinations of drugs are 
preferred.
To manage the neuropathic component of John’s bone pain a 
co-analgesic may be necessary, e.g. a low dose of prednisone. Non-
steroidal anti-inflammatory drugs (NSAIDs), with their potential 
effects on platelets, should be avoided in patients with leukaemia.[14] 
Gabapentin (e.g. Neurontin) provides good neuropathic pain cover 
and has fewer side-effects and drug interactions than the more classic 
co-analgesics, e.g. amitriptyline and carbamazepine.[15]
Doses of common co-analgesics and other drugs useful in 
managing chronic pain in children are shown in Table 5.
As John’s pain increases, he will eventually need more potent 
opioids. Morphine remains the gold standard strong opioid. Short-
acting morphine must be given regularly at 4-hourly intervals and not 
as required. Exceptions to 4-hourly dosing are in cases of hepatic or 
renal compromise, where dosing intervals are 6- and even 8-hourly. 
Extra doses (50 - 100% of the regular dose) should be provided for 
breakthrough pain.
If John’s pain settles on a regular short-acting dose every 4 
hours, long-acting morphine given every 12 hours may be more 
convenient (although some children may need 8-hourly dosing). 
To determine the dose of long-acting morphine, the total amount 
of short-acting morphine required over 24 hours should be 
calculated and halved. This dose should be rounded up or down 
to the available formulations. Long-acting morphine (e.g. MST 
Continus) is available in 10 mg, 30 mg, 60 mg and 100 mg tablet 
strengths. 
Patients on long-acting morphine may still experience breakthrough 
pain and breakthrough doses of short-acting morphine (1/6 of the 
total MST Continus dose) should be prescribed. As pain escalates, 
the dose of long-acting morphine should be increased based on the Fig. 1. The World Health Organization pain ladder.
Table 4. Commonly used analgesics for pain management in children – palliative care in the home setting
Drug Dose Notes
Paracetamol Oral: loading dose: 20 mg/kg, then 15 mg/kg/dose 6-hourly
Rectal: 30 mg/kg stat, then 20 mg/kg 4 - 6-hourly
Decrease dose and increase dosing interval to 
8-hourly in hepatic and renal impairment
Ibuprofen Oral: 5 - 10 mg/kg 6 - 8-hourly, max. 30 mg/kg/day in 3 - 4 
divided doses
Give with food
Avoid with asthma, low platelets, peptic ulcer 
disease and renal dysfunction 
Note: codeine is no longer recommended for pain management
Tramadol <50 kg: 1 - 2 mg/kg/dose 3 - 6-hourly (max. 8 mg/kg/day)
>50 kg: 50 - 100 mg 3 - 6-hourly (max. 400 mg/day)
Syrup 5 mg/ml or crush 6 × 50 mg tabs and add 
to 30 ml Ora-Plus + 30 ml Ora-Sweet solution
Tilidine Oral: 1 mg/kg/dose 6-hourly = 1 drop/2.5 kg body weight Contraindicated in head injuries with raised 
intracranial pressure, asthma
Morphine sulphate Oral: <1 month: 0.05 mg/kg/dose 4 - 6-hourly 
1 - 12 months: 0.1 mg/kg/dose 4-hourly 
>12 months: 0.2 - 0.4 mg/kg/dose 4-hourly
Subcutaneous: total oral morphine requirement over 24 hours 
divided by 2
Increase dosing interval, especially in premature 
neonates and patients with renal or hepatic 
impairment
Long-acting morphine Dose determined from total 24-hour short-acting morphine 
requirements and halved
Remember to provide short-acting breakthrough doses
Round up to available tablets: 10 mg/30 mg/60 
mg/100 mg
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breakthrough dose requirements. See an example of the calculation in 
the box above. 
What is the maximum dose of 
morphine that John may receive?
In progressive malignant disease there is no maximum dose of 
morphine, which can be scary for GPs not used to administering very 
high doses of the drug. While the most-feared side-effect is usually 
respiratory depression, pain itself is the physiological antagonist to this 
effect. Therefore, as long as the morphine dose is titrated against real 
pain, respiratory depression will not occur.[16] By definition, a potent 
opioid has no ceiling effect, i.e. increasing doses will improve pain 
control provided true tolerance has not developed (discussed below).[17] 
Morphine can either be increased in increments of 30% of the previous 
day’s dose or by calculating requirements based on the preceding 24 
hours breakthrough doses, as shown in the examples above.
What side-effects may the GP expect 
and how should these be managed?
Table 6 outlines the most common side-effects of morphine and their 
management. 
Tolerance develops to most of morphine’s minor side-effects 
(sedation, nausea and pruritus), with the exception of constipation. 
Therefore, over time (usually 3 - 5 days), the foregoing side-effects are 
no longer experienced. Clinically, this translates into either ‘waiting 
it out’ or prescribing short-term symptom control drugs (e.g. anti-
emetics) until tolerance has developed.[18] 
In adults and older children laxatives are generally prescribed 
prophylactically to avoid constipation, although in infants and 
younger children this may not always be necessary.
What would the GP do if it appeared 
that increased doses of morphine were 
no longer effective?
Tolerance is defined as a ‘phenomenon whereby chronic exposure 
to a drug diminishes its anti-nociceptive effect, or creates the need 
for a higher dose to maintain this effect’.[19] Clinically, this definition 
assumes no progression in the disease state. Increased pain is most 
commonly due to increasing tumour burden in malignancy. 
True tolerance may occasionally develop. One should then consider 
switching to a different opioid. Intolerable side-effects of one opioid may 
also warrant switching to another. Switching to fentanyl patches is common 
(as described below), but opioid rotation may be beyond the scope of the 
GP and specialist assistance should be sought. Commonly used alternative 
strong opioids include oxycodone, methadone and fentanyl.
What if John is no longer able to take 
his medication orally?
Decreased ability to take oral medication may result from difficulty 
in swallowing or more commonly because of a decreasing level of 
consciousness as death approaches. Unconscious patients still feel 
pain as the perception thereof also occurs at a subcortical level.[20] 
Sudden withdrawal of opioids can result in unpleasant withdrawal 
symptoms.[21] 
Table 5. Co-analgesics and other useful drugs in pain management in children
Drug Dose Notes
Amitriptyline 2 - 12 years: 0.1 - 0.2 mg/kg at night. Increase to max. 1 - 2 
mg/kg at night over 1 - 2 weeks
12 - 18 years: 10 - 25 mg po at night. Increase to max. 5 mg 
Do ECG before using 
Contraindicated in cases of prolonged QT interval
Pain dose is lower than for depression
Carbamazepine 5 - 20 mg/kg/day in 2 or 3 divided doses. Increase gradually 
to avoid side-effects (not the drug of choice but more readily 
available)
Induces cytochrome P450
Drug interactions with antiretrovirals
Can cause pancytopenia
Gabapentin 2 - 12 years: 3 - 5 mg/kg/dose. Start at night, then bd, then tds
Increase to 10 - 20 mg/kg/dose
12 - 18 years: 300 mg on day 1; 300 mg bd on day 2; 300 mg tds 
on day 3. Max. 1 200 mg tds
Avoid sudden withdrawal
Do not use in patients with a history of psychiatric 
illness
Corticosteroids Prednisone 1 - 2 mg/kg/day Useful for neuropathic pain, bone pain, immune 
reconstitution inflammatory syndrome
Clonidine 1 - 4 µg/kg/dose 6 - 12-hourly (useful with pain and anxiety) Caution in renal failure, vascular disease, 
depression
Diazepam 1 - 6 years: 1 mg/day in 2 - 3 divided doses 
6 - 14 years: 2 - 10 mg/day in 2 - 3 divided doses 
Use for associated anxiety and muscle spasm
Hyoscine butylbromide
(Buscopan)
1 month - 2 years: 0.5 mg/kg/dose po 8-hourly
2 - 5 years: 5 mg po 8-hourly
6 - 12 years: 10 mg po 8-hourly
Use for colicky abdominal pain
Can cause nausea, dry mouth and constipation
Example 1. Patient receives 10 mg short-acting morphine 
sulphate (syrup formulation) every 4 hours
• To convert this to long-acting morphine, use the following 
calculation:
 the total dose of morphine used over 24 hours = 10 mg × 6 
= 60 mg ÷ 2 = 30 mg. Therefore, give long-acting morphine 30 mg 
orally 12-hourly. NB: Continue to give breakthrough doses of short-
acting morphine (10 mg)
Example 2. Patient receives 30 mg long-acting morphine 
12-hourly and has received 5 breakthrough doses of 10 mg 
short-acting morphine
• To increase the dose of long-acting morphine: 
 the total morphine dose over 24 hours = (30 mg × 2) + (10 mg × 
5) = 60 mg + 50 mg = 110 mg ÷ 2 = 55 mg. MST Continus is only 
available in 10 mg, 30 mg, 60 mg and 100 mg tablet strengths. 
One could increase the dose to 60 mg 12-hourly. Continue to 
give breakthrough doses of 120 mg ÷ 6 = 20 mg of short-acting 
morphine
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A number of alternative routes can be used in the home setting, 
depending on available resources. A nasogastric tube, if acceptable and 
tolerated, can provide a useful route of drug administration, but by far 
the most widely practised alternative route in the hospice setting is via 
continuous subcutaneous infusion of drugs by means of a small portable 
pump.[22] The syringe pump (also called the ‘syringe driver’) is a simple 
battery-operated mechanical device that can be used in the home setting 
to manage almost every end-of-life symptom, provided it can be set up 
and checked regularly by a hospice nurse trained in its use.[23]
The fentanyl patch (e.g. Durogesic), which is a transdermal 
therapeutic system, is also particularly useful in managing patients 
no longer able to take regular oral morphine. A conversion table is 
used to decide on patch strength based on the 24-hour morphine 
requirements (Table 7). As it takes up to 12 hours for the patch to 
release a sufficient amount of fentanyl to achieve steady state, the 
patient should continue to receive morphine (either one long-acting 
dose or three short-acting doses) for the first 12 hours after application 
of the patch. It is important to remember that breakthrough pain 
may still be experienced when using a fentanyl patch and that extra 
morphine (an equivalent dose) must be provided. Patch strength 
should be increased according to ongoing morphine requirements. 
Patches should be changed every 72 hours, although in some patients 
(particularly children) this may need to be performed every 48 hours 
as metabolism may be more rapid. Only matrixed fentanyl patches 
(Durogesic DTrans, Durogesic SMAT, or Matrifen) may be cut.[24]
Extraordinary measures may be required to manage pain at 
the end of life, including palliative radiotherapy and short-term 
hospitalisation for intravenous therapy, especially with ketamine. If 
pain is not manageable in the home setting, the GP should consult 
with the specialist to consider hospitalisation. No child should be 
allowed to die with uncontrolled pain.
Finally, the impact of caring for a child (especially with difficult-
to-manage pain) at the end of life on the healthcare professional (GP, 
nurse, specialist) should not be underestimated and professionals 
should ensure that they care for themselves and have access to the 
necessary debriefing support when necessary.[25] A well-managed and 
expected ‘good’ death, however, can also bring with it a tremendous 
sense of professional satisfaction, despite the loss.
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Table 6. Management of common side-effects of morphine
Gastrointestinal Nausea and vomiting  Usually development of tolerance
 Haloperidol is the most commonly prescribed anti-emetic
Constipation  Laxatives (prophylactic in older children and adults)
Autonomic Xerostomia  Good oral care, ice cubes
Urinary retention  Bladder massage, urinary antispasmodics, catheterisation
Central nervous system Drowsiness  Usually development of tolerance. Methylphenidate has been used in chronic cases
Respiratory depression  Naloxone
Myoclonus  Baclofen, diazepam, opioid rotation
Hyperalgesia  Opioid rotation
Cutaneous Itch  Antihistamines or paroxetine, opioid rotation if chronic
Sweating  Symptomatic
Table 7. Conversion table: Oral morphine to fentanyl patch 
24-hour oral morphine requirement (mg) <67 68 - 135 135 - 224 225 - 314 315 - 404 405 - 494 495 - 584 
Fentanyl patch (µg) 12 25 50 75 100 125 150 
